TEVIMBRA (tislelizumab-jsgr) injection

TEVIMBRA is a prescription medicine used to treat non-small cell lung cancer (NSCLC). FDA approved tislelizumab-jsgr (brand name TEVIMBRA) is not (yet) registered or available in India but on request Indian patient can buy TEVIMBRA at the lowest price.

TEVIMBRA (tislelizumab-jsgr) injection Price Delhi India
TEVIMBRA (tislelizumab-jsgr) injection

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

TEVIMBRA (tislelizumab-jsgr) injection

Tislelizumab, sold under the brand name Tevimbra among others, is an anti-cancer medication used for the treatment of various forms of cancer

Tevimbra is used to treat adults with NSCLC that is advanced or has spread to other parts of the body (metastatic). Tevimbra is used together with chemotherapy as first-line treatment for patients whose cancer cannot be removed surgically (unresectable) or treated with a combination of chemotherapy and radiotherapy.

Tislelizumab, sold under the brand name Tevimbra among others, is an anti-cancer medication used for the treatment of various forms of cancer. It is a humanized monoclonal antibody directed against programmed death receptor-1. Tislelizumab was approved for medical use in China in December 2019, in the European Union in September 2023, in the United States in March 2024, and in Australia in May 2024.

It is used to treat various cancers by helping the immune system fight cancer cells. Tislelizumab is approved in several countries, including the US, EU, and Australia, for different types of cancers, particularly esophageal and gastric cancers.

TEVIMBRA (tislelizumab-jsgr) injection, for intravenous use Initial U.S. Approval: 2024
—————-
Current Indication: Treat non-small cell lung cancer (NSCLC)
—————-
Marketed By: BeiGene
—————-
Approval Date: : 2024
—————-
Active ingredients: tislelizumab-jsgr
—————-
Inactive ingredients: citric acid monohydrate, histidine, L-histidine hydrochloride monohydrate, polysorbate 20,
sodium citrate, Sterile Water for Injection, and trehalose.

—————-

Injection: 100 mg/10 mL (10 mg/mL) solution in a single-dose vial.

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.